Introducing pathogen reduction technology in Poland: A cost-utility analysis

Transfusion Medicine and Hemotherapy

Volumn 42, Issue 3, 2015, Pages 158-165

  Agapova, Maria ^a   Lachert, Elzbieta ^b   Brojer, Ewa ^b   Letowska, Magdalena ^b   Grabarczyk, Piotr ^b   Custer, Brian ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood safety; Cost effectiveness; ICER; Mirasol PRT; Pathogen reduction technology; Poland

Indexed keywords

FRESH FROZEN PLASMA;

ARTICLE; BACTEREMIA; BACTERIUM CONTAMINATION; BLOOD SAFETY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MORTALITY; PATHOGEN REDUCTION SYSTEM; POLAND; POSTTRANSFUSION HEPATITIS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SCREENING; SEPSIS; VIRAL CONTAMINATION;

EID: 84931061022     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000371664     Document Type: Article

References (31)

1. Poland's Ministry of Health Selects CaridianBCT Mira-sol System for Blood Supply Safety. Medical Devices Business Review. 2009. http://invitrodiagnostics.medical-devices-business-review.com/news/polands-ministry-of- health-selects-caridianbct-mirasol-system-for-blood- supply-safety-100624 (last accessed March 31, 2015).
2. Custer B, Agapova M, Martinez RH: The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-2473.
3. Héma-Québec Annual Report 2013-2014. 2014. www.hema-quebec.qc.ca/userfiles/file/RA-2013-2014/HQ- RA-2013-2014-ANG-FINAL(1).pdf (last accessed March 31, 2015).
4. Canadian Blood Services Annual Report. A Report for Canadians 2012/2013. 2013. http://video.bloodservices. ca/Annual2013/index.html (last accessed March 31, 2015).
5. Antoniewicz-Papis J, Letowska M: The Polish Blood Transfusion Service-quality, guidelines, laws, selected topics of interest and future challenges. Transfus Med Hemother 2006;33:401-406.
6. WHO: CHOosing Interventions That Are Cost Effective (WHO-CHOICE) 2007. www.who.int/choice/country/pol/cost/en/index.html (last accessed March 31, 2015).
7. Rosiek A, Tomaszewska A, Lachert E, Antoniewicz-Papis J, Poglod R, Letowska M: Blood Transfusion Service in Poland in 2011. J Transfus Med 2012;5:159-170.
8. Brojer E: Annual Report from the Regional Blood Center. Warsaw, Poland, 2009.
9. European Center for Disease Control: West Nile Virus Transmission in Europe. Solna, European Center for Disease Control, 2010. www.ecdc.europa.eu/en (last accessed March 31, 2015).
10. Schrezenmeier H, Walther-Wenke G, Muller TH, We-inauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Forstemann E, Gebauer W, Hochsmann B, Karakassopoulos A, Liebscher UM, Sanger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-652.
11. Letowska M: Medical Standards for Collection, Preparation and Distribution of Blood and Blood Components for Public Blood Establishments; Collective Work, 2nd ed. Warsaw, Institute of Hematology and Transfusion Medicine, 2011.
12. Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M: Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007;47:421-429.
13. Brecher ME, Hay SN: Bacterial contamination of blood components. Clin Microbiol Rev 2005;18:195-204.
14. Briggs A, Claxton, Karl, Sculpher M: Decision Modelling for Health Economic Evaluation (Handbooks for Health Economics Evaluation). Oxford, Oxford University Press, 2006.
15. Weusten J, Vermeulen M, van Drimmelen H, Lelie N: Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-215.
16. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S: Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion 2013;53(suppl 3):2399-2412.
17. OECD (2010), OECD.Stat, (database). http://stats.oecd. org/index.aspx?DataSetCode=PPPGDP (last accessed March 31, 2015).
18. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Mel-bye M, Edgren G, Nyren O, Reilly M, Norda R, Ti-tlestad K, Tynell E, Hjalgrim H: Survival after blood transfusion. Transfusion 2008;48:2577-2584.
19. Pietersz RN, Reesink HW, Panzer S, Oknaian S, Ku-perman S, Gabriel C, Rapaille A, Lambermont M, Deneys V, Sondag D, Ramírez-Arcos S, Goldman M, Delage G, Bernier F, Germain M, Vuk T, Georgsen J, Morel P, Naegelen C, Bardiaux L, Cazenave JP, Dreier J, Vollmer T, Knabbe C, Seifried E, Hourfar K, Lin CK, Spreafico M, Raffaele L, Berzuini A, Prati D, Satake M, de Korte D, van der Meer PF, Kerkhoffs JL, Blanco L, Kjeldsen-Kragh J, Svard-Nilsson AM, McDonald CP, Symonds I, Moule R, Brailsford S, Yomtovian R, Jacobs MR: Bacterial contamination in platelet concentrates. Vox Sang 2014;106:256-283.
20. Walther-Wenke G, Wirsing von Konig CH, Däubener W, Heiden M, Hoch J, Hornei B, Volkers P; Working Party on Bacteria Safety in Transfusion Medicine, Advisory Board of the German Ministry of Health, Berlin: Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011;100:359-366.
21. Vuk T, Barisic M, Hecimovic A, Rukavina L, Batarilo I, Šarlija D, Jukić I: Bacterial contamination of blood products at the Croatian Institute of Transfusion Medicine: results of eleven-year monitoring. Transfus Med 2012;22:432-439.
22. Funk MB, Lohmann A, Guenay S, Henseler O, Heiden M, Hanschmann KM, Keller-Stanislawski B: Transfusion-transmitted bacterial infections-haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 2011;38:266-271.
23. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA: Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006;46:956-965.
24. Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U: Cost-effectiveness of pathogen inactiva-tion for platelet transfusions in the Netherlands. Transfus Med 2005;15:379-387.
25. Marschner S, Goodrich R: Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemo-ther 2011;38:8-18.
26. Jackson BR, Busch MP, Stramer SL, AuBuchon JP: The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-729.
27. Davidson T, Ekermo B, Gaines H, Lesko B, Akerlind B: The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion 2011;51:421-429.
28. International Forum: Haemovigilance. Vox Sang 2006; 90:207-241.
29. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Cas-tren J, Naukkarinen M, Assal A, Jork C, Hourfar MK, Michel P, Offergeld R, Pichl L, Schmidt M, Schottstedt V, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin CK, Tsoi WC, O'Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelmann M, Flanagan P, Flesland O, Brojer E, Letowska M, Nascimento F, Zhiburt E, Chua SS, Teo D, Stezinar SL, Vermeulen M, Reddy R, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster G, Jennings C, Notari E, Stramer S, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
30. Blajchman MA, Goldman M, Freedman JJ, Sher GD: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukore-duction. Transfus Med Rev 2001;15:1-20.
31. Serious Hazards of Transfusion: Annual Report Summary 2007. Manchester, SHOT, 2008.